| Similar Articles |
|---|
 |
Chemistry World
July 3, 2012
Andrew Turley |
BMS and AstraZeneca buy Amylin for $7bn Pharma giants Bristol-Myers Squibb and AstraZeneca have teamed up to buy US biotech Amylin for $7 billion, further strengthening their position in the burgeoning market for diabetes drugs.   |
Chemistry World
March 14, 2014
Phillip Broadwith |
Bristol-Myers Squibb to close Irish plant BMS tied the closure to 'changing market demand' for its products, along with efforts to optimize its manufacturing network. |
Chemistry World
June 5, 2015
Rebecca Trager |
BMS sues executive for joining rival company Bristol-Myers Squibb has filed a lawsuit against a former executive who quit suddenly last month to work for a direct competitor, AstraZeneca. |
The Motley Fool
February 1, 2008
Brian Lawler |
Credit Crisis Bites Big Pharma Bristol-Myers Squibb takes a $275 million writedown in its investment portfolio for the quarter. |
Chemistry World
October 7, 2015
Phillip Broadwith |
Bristol-Myers-Squibb fined for alleged Chinese bribes The US Securities and Exchange Commission has fined New York based pharmaceutical company Bristol-Myers Squibb over $14 million over alleged bribes made to Chinese state owned hospitals. |
The Motley Fool
September 15, 2008
Brian Orelli |
Side Effects Don't Scare Icahn Billionaire investor Carl Icahn upped his stake in the drug company by almost 50% and now owns 7.3% of the company. |
Chemistry World
January 11, 2016
Phillip Broadwith |
GSK's ViiV to buy HIV drugs from BMS Bristol-Myers Squibb has agreed to sell its entire portfolio of investigational HIV drugs as the company seeks to exit research in virology. |
American Family Physician
February 15, 2002 |
Burning Mouth Syndrome What is burning mouth syndrome?... What causes BMS?... How can my doctor tell if I have BMS?... How is BMS usually treated?... |
The Motley Fool
May 16, 2011
Brian Orelli |
Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly. |
Chemistry World
November 3, 2015
Phillip Broadwith |
Bristol-Myers Squibb to buy Cardioxyl for heart drug The deal gives BMS full rights to develop CXL-1427, an experimental drug for acute decompensated heart failure, currently in Phase II clinical trials. |
Chemistry World
December 20, 2013
Patrick Walter |
AstraZeneca shells out $4.1bn for diabetes business AstraZeneca has agreed to pay Bristol-Myers Squibb up to $4.1 billion for its share of the pharma giants' diabetes joint venture. |
Bio-IT World
July 14, 2004 |
Not Just a Day at the Beach Joseph Panetta recalls leaving the comfort of a pharma job in Philadelphia for a position in biotech in San Diego, whose fledgling biotech community survived stormy nascent years to mushroom into a biotech hotbed. |
The Motley Fool
January 30, 2009
Brian Orelli |
Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%. |
The Motley Fool
November 18, 2008
Brian Orelli |
Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere. |
The Motley Fool
November 8, 2011
Tim Beyers |
Amylin Pharmaceuticals Shares Plummeted: What You Need to Know Is this meaningful, or just another movement for Amylin Pharmaceuticals? |
The Motley Fool
October 20, 2011
Travis Hoium |
Amylin Pharmaceuticals Shares Jumped: What You Need to Know Shares of Amylin Pharmaceuticals jumped 11% today after the company released great earnings and pipeline news. |
The Motley Fool
May 26, 2011
Brian Orelli |
Amylin Scores First in Court But it is still early innings. |
Chemistry World
July 8, 2014
Phillip Broadwith |
First of a new breed of anticancer antibodies approved in Japan Ono pharmaceuticals' Opdivo (nivolumab) has been approved for treating melanomas where surgery is impossible. |
Pharmaceutical Executive
August 1, 2005
Joanna Breitstein |
Weathering the Storm Out from financial scandal, CEO Peter Dolan is steering Bristol-Myers Squibb's most productive pipeline yet. |
The Motley Fool
June 24, 2010
Luke Timmerman |
Amylin Cuts 60 Jobs The pharmaceutical company says research is still a priority. |
The Motley Fool
August 17, 2010
Travers & Jayson |
How Long Can Amylin Pharmaceuticals Last? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. |
Chemistry World
February 14, 2013
Andrew Turley |
BMS sells OTC drugs for $482m UK consumer goods giant Reckitt Benckiser has struck a $482 million deal to buy from Bristol-Myers Squibb rights to a range of over-the-counter drugs in parts of Latin America, including Brazil and Mexico. |
Chemistry World
October 3, 2013
Laura Howes |
Chemist sentenced to life A US-based chemist has been sentenced to life for murdering her husband with thallium that she obtained from her work at Bristol-Myers Squibb. |
Chemistry World
April 9, 2015
Emma Stoye |
BMS invests in gene therapy Bristol-Myers Squibb has agreed to invest over $100 million in Netherlands-based biotechnology company uniQure, which specializes in gene therapies for cardiovascular diseases. |
The Motley Fool
January 29, 2008
Brian Orelli |
No Weight Loss at Amylin Bulging costs related to its diabetes drug Byetta keep the drugmaker from showing a profit this quarter. |
The Motley Fool
April 22, 2008
Brian Orelli |
Amylin Treads Water One-drug wonders like Amylin Pharmaceuticals can't get away with stagnant growth. |
BusinessWeek
January 9, 2006
Arlene Weintraub |
Bucking The Odds at Amylin With Ginger Graham at the helm, Amylin Pharmaceuticals has two approved diabetes drugs. |
The Motley Fool
April 16, 2009
Brian Orelli |
Icahn: Ludicrous and Arrogant Fun to read, but does he have the best intentions for long-term shareholders? |
The Motley Fool
July 22, 2010
Brian Orelli |
It's All About the Future for Amylin Its second quarter stank, but there's a lot up ahead. |
The Motley Fool
May 25, 2007
Brian Orelli |
Amylin Sifts for Gold The biotech mines extra value from its compound library. Investors, take note. |
The Motley Fool
August 23, 2005
Stephen D. Simpson |
A Cure for Amylin's Stock? Shares moved up after promising results from a diabetes-drug test. But will the gains last? |
